Details
Stereochemistry | RACEMIC |
Molecular Formula | C14H21N2O3.Na |
Molecular Weight | 288.3179 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCCCC1C(=O)[N-]C(=O)N(C2CCCCC2)C1=O
InChI
InChIKey=SGESMFOVCAMYRA-UHFFFAOYSA-M
InChI=1S/C14H22N2O3.Na/c1-2-3-9-11-12(17)15-14(19)16(13(11)18)10-7-5-4-6-8-10;/h10-11H,2-9H2,1H3,(H,15,17,19);/q;+1/p-1
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/10497145Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18445991 and http://www.genome.jp/dbget-bin/www_bget?drug+D01661
Sources: http://www.ncbi.nlm.nih.gov/pubmed/10497145
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18445991 and http://www.genome.jp/dbget-bin/www_bget?drug+D01661
Bucolome (Paramidine) is a barbiturate derivative. It is a non-steroidal anti-inflammatory drug, which is used in the treatment of chronic articular rheumatism. It has been used as a uricosuric and/or anti-inflammatory agent in Japan since 1967. Bucolome acts as a CYP2C9 inhibitor and reduces the metabolism of several commonly used drugs, which makes it useful for potentiating or extending the duration of action of those drugs, or reducing the production of unwanted metabolites.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3397 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10497145 |
8.24 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | PARAMIDIN Approved UseAntirheumatic and antigout drug |
PubMed
Title | Date | PubMed |
---|---|---|
Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome. | 2005 Apr |
|
[Intraluminal ureteral hematoma complicating anticoagulant therapy]. | 2005 Jul |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/11304904
300 mg dose of bucolome once a day
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/15640375
Protein binding of furosemide (20 M) was significantly inhibited by 300 M
bucolome in human serum
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
0QN61326HC
Created by
admin on Sat Dec 16 10:56:58 GMT 2023 , Edited by admin on Sat Dec 16 10:56:58 GMT 2023
|
PRIMARY | |||
|
23670498
Created by
admin on Sat Dec 16 10:56:58 GMT 2023 , Edited by admin on Sat Dec 16 10:56:58 GMT 2023
|
PRIMARY | |||
|
6891-28-7
Created by
admin on Sat Dec 16 10:56:58 GMT 2023 , Edited by admin on Sat Dec 16 10:56:58 GMT 2023
|
PRIMARY | |||
|
DTXSID30988620
Created by
admin on Sat Dec 16 10:56:58 GMT 2023 , Edited by admin on Sat Dec 16 10:56:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD